How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's ChallengesThe Motley Fool • 06/23/21
12 Words From CureVac's CEO That Could Mean Billions for Moderna and PfizerThe Motley Fool • 06/18/21
Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing DataBenzinga • 06/18/21
German biotech CureVac's stock plunges 50% after its COVID-19 vaccine candidate failed a clinical trialBusiness Insider • 06/17/21
Coronavirus tally: Global cases of COVID-19 top 177 million and CureVac vaccine is just 47% effectiveMarket Watch • 06/17/21
CureVac shares tank 50% after preliminary data shows Covid vaccine is only 47% effectiveCNBC • 06/16/21
CureVac's COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotechBusiness Insider • 06/16/21